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Scores were considered useful if AUROC was >0.7 and excellent
if >0.8.
Results: 332 patients with severe AH were treated with
prednisolone 40mg/day. At ﬁrst day of treatment, patients had
the following characteristics (results in medians): male gender
55.9%, ascites 74.2%, encephalopathy 24.3%, age 50.5years (95%CI:
49.2–51.7), alcohol consumption 100g/day (80–100), prothrombin
time 20.9sec (20.3–21.8), INR 1.9 (1.85–2), AST 109 IU/l (102–117),
albumin 25g/l (24.1–26), bilirubin 15.6mg/dl (13.4–18), creatinine
0.86mg/dl (0.8–0.9). At ﬁrst day of treatment with steroids,
median of prognostic functions were: ABIC 8.3 (8–8.5), Glasgow
9 (8–9), Lille 0.31 (0.25–0.37), Maddrey 60.3 (56.2–63.4) and
MELD 22.5 (21.2–23.6). The AUROC (0.84) of the Lille score was
signiﬁcantly higher than the AUROC of other scores: ABIC (0.76,
p = 0.008), Glasgow (0.68, p = 0.0004), Maddrey (0.65, p < 0.00001)
and MELD (0.7, p = 0.0002). The AUROC for ABIC score was higher
than for Glasgow (p=0.003), Maddrey (p < 0.0001) and MELD
(p =0.002). The diagnostic accuracy of the scores using baseline
variables was not improved by their evolution between 1st and
7th day of treatment: ABIC 0.68, Glasgow 0.65, Maddrey 0.65,
MELD 0.64. We compared the ability of the Lille, Glasgow and ABIC
scores to classify patients according to their proposed cut-offs (9 for
the ABIC and Glasgow scores, 0.45 for the Lille score). Percentage
of patients correctly classiﬁed by these cut-offs was higher for the
Lille score than for the ABIC (79.2% vs. 72%, p = 0.01) and of the
Glasgow scores (62.8%, p < 0.01).
Conclusion: In a prospective cohort of more than 300 patients,
the ABIC and the MELD scores are clinically useful and the Lille
score has an excellent diagnostic accuracy for predicting deaths at
6 months. In addition, the 0.45 cut-off of Lille score is superior in
terms of patients correctly classiﬁed.
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Background: Endstage alcoholic liver disease is generally treated in
terms of the complications of portal hypertension but alcohol also
causes cardiac myopathy and this may complicate the management
of the liver disease. Excess daily alcohol ingestion for 5 years
can lead to alcoholic cardiomyopathy (AC) which can have a long
asymptomatic phase and so can be under diagnosed. An audit was
formulated to assess this potential disease burden within Western
Health, a community based hospital system with 800 inpatient
beds.
Method: 2 patient cohorts were selected to compare and contrast
the potential for missed diagnoses. One cohort consisted of 17
gastroenterology in-patients under the care of our in unit on a single
day. The other retrospective cohort consisted of 50 consecutive
recent admissions with alcohol abuse. All case histories were
reviewed for signiﬁcant alcohol intake, clinical evidence consistent
with AC and whether or not they had been assessed with an
echocardiogram. All chest x-rays (CXR) were reviewed for evidence
of cardiomegaly and signs of cardiac failure.
Results: Of the in-patient cohort of 17, there were 5 (29%) alcoholics
with cardiomegaly. There were 4 (24%) cases of at least early AC,
2 of which were symptomatic. All patients with cardiomegaly or AC
had a diagnosis of cirrhosis. Of the recent admission cohort of 50
patients, 25 (50%) had signiﬁcant alcohol intake and cardiomegaly
on the CXR. 9 (36%) of these 25 had symptoms or signs of cardiac
failure, 8 (32%) had echocardiograms and 3 had diagnosed AC.
The majority (76%) of this second cohort with cardiomegaly had
cirrhosis.
Conclusion: Half the recent admissions to our unit, with a
signiﬁcant history of alcohol intake, had cardiomegaly but most
had not had an echocardiogram. The majority of those with
cardiomegaly have cirrhosis. The presence of cardiomyopathy has
implications for management, in particular for ﬂuid replacement
and suitability for liver transplant. Continued alcohol consumption
will worsen cardiac function in addition to also damaging the
liver. Abstinence has been shown previously to improve prognosis.
A prospective study is underway to conﬁrm the initial data and
explore the impact on disease management.
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Background and Aims: Hepatic enzyme CYP2E1 is involved in the
metabolism of a number of exogenous and endogenous substances
(i.e. ethanol, drugs and chemical carcinogens). Being polymorphic,
CYP2E1 gene can give different xeno-metabolic capabilities in a
population and it is well known that inadequate or no enzymatic
deactivation of xenobiotics could induce an increased susceptibility
to disease and cancer. In particular, one of the 5′-ﬂanking region
polymorphisms, able to differentiate CYP2E1 gene transcriptional
activity, is caused by the appearance/disappearance of RsaI and
PstI restriction sites, which generates two different alleles, namely
*C1(Rsa+/Pst−) and *C2(Rsa−/Pst+) respectively, reported to be in
complete linkage disequilibrium.
Methods: To conﬁrm the existence of a correlation between some
particular CYP2E1 genotypes/haplotypes and hepatocarcinoma, we
determined CYP2E1 PstI/RsaI genotypes/haplotypes by RFLP-PCR in
a cohort of central western Sicily hepatocarcinoma patients and in
a population of healthy students from the same geographic area.
Results: In hepatocarcinoma patients, modal genotype association
was Rsa++/Pst−−, corresponding to CYP2E1 *C1/*C1 haplotype,
whereas the Rsa+−/Pst−+ association, equivalent to CYP2E1 *C1/*C2
haplotype, resulted to have the lowest frequency both in patients
and in controls. Moreover, both in patients and in controls, non-
canonical genotype associations were frequent and arose from
a no-linkage disequilibrium between the two polymorphic sites.
Other authors reported this ﬁnding as a rare occurrence. Thus,
from analysis of only one restriction site, Rsa++ genotype was
approximately 1.5-fold more frequent in patients than in controls,
and the non-canonical Rsa+− genotype was found relatively
frequent in patients. Moreover, HuH7 and HA22T transformed
hepatocarcinoma cell lines also showed the Rsa+− genotype.
Conclusions: These results suggest that the presence in CYP2E1
genotype of at least one allele with an Rsa I restriction site is
correlated with hepatocarcinoma. As this site is known a consensus
sequence for some speciﬁc CYP gene transcription factors, like
HNF-1, it may be supposed that a single nucleotide polymorphism
can alter the possibility of HNF-1 to bind CYP2E1 promoter. This
could determine a marked change in the transcriptional activity
of the gene, incompetence in xenobiotic metabolism or in toxic
substance deactivation and an increased susceptibility to neoplastic
diseases, such as hepatocarcinoma.
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